Skip to content


Recarbrio (relebactam) is a small molecule pharmaceutical. Relebactam was first approved as Recarbrio on 2019-07-16. It is used to treat intraabdominal infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections. Recarbrio's patent is valid until 2029-11-19 (FDA).
Trade Name Recarbrio
Common Name Relebactam
Indication gram-negative bacterial infections, intraabdominal infections, pyelonephritis, urinary tract infections
Drug Class Beta-lactamase inhibitors
Get full access now